Cargando…
Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility....
Autores principales: | Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Iyer, Swaminathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647727/ https://www.ncbi.nlm.nih.gov/pubmed/35470385 http://dx.doi.org/10.1182/bloodadvances.2020003971 |
Ejemplares similares
-
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
por: Horwitz, S., et al.
Publicado: (2022) -
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020) -
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
por: Cranmer, Holly, et al.
Publicado: (2022) -
Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
por: Hamadani, Mehdi
Publicado: (2022) -
Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)